Literature DB >> 22178455

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Pilar Eroles1, Ana Bosch, J Alejandro Pérez-Fidalgo, Ana Lluch.   

Abstract

The last decade has brought a breakthrough in the knowledge of the biology of breast cancer. The technological development, and in particular the high throughput technologies, have allowed researchers to inquire more deeply into the nature of the disease through the comparative study of large numbers of samples. The classification of breast cancer by traditional parameters has been joined by rankings based on gene expression. Among the most popular platforms are MammaPrint®, Oncotype DX® the wound-response model, the rate of two genes model, the genomic grade index and the intrinsic subtype model. The latter one provides the amplest biological information and allows for the classification of breast cancer into six intrinsic subtypes: luminal A, luminal B, HER2-enriched, basal-like, normal breast and claudin-low. These new classifications are not yet fully applicable to clinical practice not only because they have not been standardized, but also because they entail a substantial economic outlay. Nevertheless, they have provided valuable information on tumor biology that has led to a better understanding of the signaling pathways governing the processes of formation, maintenance and expansion of the tumors. Researchers now know more about the HER2, estrogen receptor, IGF1R, PI3K/AKT, mTOR, AMPK and angiogenesis pathways which has allowed for the development of new targeted therapeutics now being tested in ongoing clinical trials. In general, one can say that the last decade has changed the way researchers understand, classify and study breast cancer, and it has reshaped the way doctors diagnose and treat this disease. In addition, it has undoubtedly changed the search for alternative therapies by integrating molecular studies and the selection of study populations based on their molecular markers into clinical trials. The present review summarizes the advances that have allowed researchers to both better classify the disease, as well as explore some of the most important signaling pathways.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178455     DOI: 10.1016/j.ctrv.2011.11.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  179 in total

Review 1.  RUNX1-dependent mechanisms in biological control and dysregulation in cancer.

Authors:  Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2018-12-04       Impact factor: 6.384

2.  Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

Authors:  Matthew F Buas; Jung-hyun Rho; Xiaoyu Chai; Yuzheng Zhang; Paul D Lampe; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2015-08-30       Impact factor: 4.872

3.  Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.

Authors:  Sunil Acharya; Jun Yao; Ping Li; Chenyu Zhang; Frank J Lowery; Qingling Zhang; Hua Guo; Jingkun Qu; Fei Yang; Ignacio I Wistuba; Helen Piwnica-Worms; Aysegul A Sahin; Dihua Yu
Journal:  Cancer Res       Date:  2019-06-25       Impact factor: 12.701

Review 4.  Prognostic value of survivin expression in breast cancer patients: a meta-analysis.

Authors:  Jian Song; Hong Su; Yang-Yang Zhou; Liang-Liang Guo
Journal:  Tumour Biol       Date:  2013-05-21

Review 5.  Phospholipase Signaling in Breast Cancer.

Authors:  Yu Jin Lee; Kyeong Jin Shin; Hyun-Jun Jang; Dong-Young Noh; Sung Ho Ryu; Pann-Ghill Suh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Digital image analysis outperforms manual biomarker assessment in breast cancer.

Authors:  Gustav Stålhammar; Nelson Fuentes Martinez; Michael Lippert; Nicholas P Tobin; Ida Mølholm; Lorand Kis; Gustaf Rosin; Mattias Rantalainen; Lars Pedersen; Jonas Bergh; Michael Grunkin; Johan Hartman
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

7.  Foxa1 is essential for mammary duct formation.

Authors:  Yi Liu; Yongbing Zhao; Benjamin Skerry; Xiao Wang; Christelle Colin-Cassin; Derek C Radisky; Klaus H Kaestner; Zhaoyu Li
Journal:  Genesis       Date:  2016-03-29       Impact factor: 2.487

Review 8.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25

9.  Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation.

Authors:  Ting Zhu; Zhengxiang Ji; Caixia Xu; Zhiyang Peng; Liang Gu; Rui Zhang; Yangchen Liu
Journal:  J Mol Histol       Date:  2014-07-16       Impact factor: 2.611

10.  The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.

Authors:  Juan Xu; Xiyi Chen; Yu Sun; Yaqian Shi; Fang Teng; Mingming Lv; Chen Liu; Xuemei Jia
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.